Tags

Type your tag names separated by a space and hit enter

Antidiabetic activity of Syzygium calophyllifolium in Streptozotocin-Nicotinamide induced Type-2 diabetic rats.
Biomed Pharmacother. 2016 Aug; 82:547-54.BP

Abstract

The study was initiated to determine the antidaibetic activity of Syzygium calophyllifolium in Streptozotocin-Nicotinamide (STZ-NA) induced diabetic rats. The rats were treated with 100 and 200mg/kg of the Syzygium calophyllifolium bark methanol extract (SCBM) and compared with the diabetic, normal and standard glibenclamide groups. The blood glucose level and body weight of the rats in different groups were monitored at regular intervals. The serum, blood biochemical and histopathological parameters of liver, kidney and pancreas were also analyzed. In vivo antioxidants like SOD, CAT, GST, GSH and GR levels were estimated in liver and kidney. SCBM (100mg/kg) extract could reduce the blood glucose level from the 15th day itself (213.67mg/dL) and the best reduction was observed till the end of the study with 259.25mg/dL (200mg/kg). Initial decrease in body weight was recovered after drug treatment and an increase in body weight was observed on the 4th week. The haematological parameters like total haemoglobin, packed cell volume percentage, total WBC and RBC content were found normal compared to that of normal untreated rats. Glibenclamide was also equally effective. The higher dose of SCBM extract could normalize the triglycerides, HDL, cholesterol and VLDL constituents in blood serum to the levels almost similar to that of normal rats. The results of the in vivo antioxidant levels showed that there are no significant difference in SOD, GSH and GR levels in all the groups compared to the normal control. SCBM and SMBM at 200mg/kg dose were much effective over the lower dose. The histology revealed that SCBM 200mg/kg could protect the cellular architecture of liver kidney and pancreas. The results from the study confirm ethnopharmacological significance of the plant and could be taken further for the development of an effective pharmaceutical drug against diabetes.

Authors+Show Affiliations

Bioprospecting Laboratory, Department of botany, Bharathiar University, Tamil Nadu, Coimbatore, India.Bioprospecting Laboratory, Department of botany, Bharathiar University, Tamil Nadu, Coimbatore, India. Electronic address: drparimel@gmail.com.Department of Pharmacy, Federal University of Sergipe, Aracaju, Sergipe, Brazil.Bioprospecting Laboratory, Department of botany, Bharathiar University, Tamil Nadu, Coimbatore, India.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27470395

Citation

Chandran, Rahul, et al. "Antidiabetic Activity of Syzygium Calophyllifolium in Streptozotocin-Nicotinamide Induced Type-2 Diabetic Rats." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 82, 2016, pp. 547-54.
Chandran R, Parimelazhagan T, Shanmugam S, et al. Antidiabetic activity of Syzygium calophyllifolium in Streptozotocin-Nicotinamide induced Type-2 diabetic rats. Biomed Pharmacother. 2016;82:547-54.
Chandran, R., Parimelazhagan, T., Shanmugam, S., & Thankarajan, S. (2016). Antidiabetic activity of Syzygium calophyllifolium in Streptozotocin-Nicotinamide induced Type-2 diabetic rats. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 82, 547-54. https://doi.org/10.1016/j.biopha.2016.05.036
Chandran R, et al. Antidiabetic Activity of Syzygium Calophyllifolium in Streptozotocin-Nicotinamide Induced Type-2 Diabetic Rats. Biomed Pharmacother. 2016;82:547-54. PubMed PMID: 27470395.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antidiabetic activity of Syzygium calophyllifolium in Streptozotocin-Nicotinamide induced Type-2 diabetic rats. AU - Chandran,Rahul, AU - Parimelazhagan,Thangaraj, AU - Shanmugam,Saravanan, AU - Thankarajan,Sajeesh, Y1 - 2016/06/06/ PY - 2016/04/20/received PY - 2016/05/23/revised PY - 2016/05/23/accepted PY - 2016/7/30/entrez PY - 2016/7/30/pubmed PY - 2017/2/9/medline KW - Antidiabetic activity KW - Glibenclamide KW - Streptozotocin-nicotinamide KW - Syzygium calophyllifolium KW - Type 2 diabetes SP - 547 EP - 54 JF - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JO - Biomed Pharmacother VL - 82 N2 - The study was initiated to determine the antidaibetic activity of Syzygium calophyllifolium in Streptozotocin-Nicotinamide (STZ-NA) induced diabetic rats. The rats were treated with 100 and 200mg/kg of the Syzygium calophyllifolium bark methanol extract (SCBM) and compared with the diabetic, normal and standard glibenclamide groups. The blood glucose level and body weight of the rats in different groups were monitored at regular intervals. The serum, blood biochemical and histopathological parameters of liver, kidney and pancreas were also analyzed. In vivo antioxidants like SOD, CAT, GST, GSH and GR levels were estimated in liver and kidney. SCBM (100mg/kg) extract could reduce the blood glucose level from the 15th day itself (213.67mg/dL) and the best reduction was observed till the end of the study with 259.25mg/dL (200mg/kg). Initial decrease in body weight was recovered after drug treatment and an increase in body weight was observed on the 4th week. The haematological parameters like total haemoglobin, packed cell volume percentage, total WBC and RBC content were found normal compared to that of normal untreated rats. Glibenclamide was also equally effective. The higher dose of SCBM extract could normalize the triglycerides, HDL, cholesterol and VLDL constituents in blood serum to the levels almost similar to that of normal rats. The results of the in vivo antioxidant levels showed that there are no significant difference in SOD, GSH and GR levels in all the groups compared to the normal control. SCBM and SMBM at 200mg/kg dose were much effective over the lower dose. The histology revealed that SCBM 200mg/kg could protect the cellular architecture of liver kidney and pancreas. The results from the study confirm ethnopharmacological significance of the plant and could be taken further for the development of an effective pharmaceutical drug against diabetes. SN - 1950-6007 UR - https://www.unboundmedicine.com/medline/citation/27470395/Antidiabetic_activity_of_Syzygium_calophyllifolium_in_Streptozotocin_Nicotinamide_induced_Type_2_diabetic_rats_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0753-3322(16)30523-6 DB - PRIME DP - Unbound Medicine ER -